CUPERTINO — A federal appeals court has decided to revive a U.S. sales ban on Apple’s premium watches while it referees a patent dispute revolving around a sensor, raising the specter that the company will pull the devices from stores for the second time in less than a month.
The ruling issued Wednesday by the U.S. Court of Appeals in Washington comes three weeks after it blocked the ban. That temporary stay enabled Apple to renew sales of the two internet-connected watch models, the Series 9 and Ultra 2, embroiled in an intellectual-property fight with medical technology company Masimo.
The U.S. International Trade Commission in late October ruled a blood-oxygen sensor in the Apple Watch models infringed on Masimo’s patents, resulting in Apple briefly ceasing sales of the Series 9 and Ultra 2 in late December before getting the short-lived reprieve from the appeals court.
Apple is still trying to persuade the federal appeals court to overturn the ITC’s ruling, but Wednesday’s decision means the company is no longer insulated from the U.S. sales ban.
The Federal Circuit’s decision to lift the temporary stay is a victory for the integrity of the American patent system and the safety of people relying on pulse oximetry,” said Joe Kiani, founder and CEO of Masimo, in a statement Wednesday evening. “It affirms that even the largest and most powerful companies must respect the intellectual rights of American inventors and must deal with the consequences when they are caught infringing others’ patents.”
In a statement Wednesday evening provided to 9to5Mac, Apple said it would begin Thursday selling versions of the Series 9 and Ultra 2 “without the Blood Oxygen feature.”
The appeals court decision revives the ban beginning at 2 p.m. Pacific Time Thursday.
The appeals process is expected to take at least a year, meaning Apple will be forced to stop selling its latest watch models in the U.S. through 2024 or perhaps redesign the devices in a way that complies with the ITC’s ruling.
In a Monday court filing, Masimo disclosed Apple has won approval from the U.S. Customs and Border Protection on revisions that would remove the blood-oxygen sensor from the watches.
The Cupertino-based company also could negotiate a settlement with Masimo that would clear the way for it to continue selling the Apple Watch models with the blood-oxygen sensor. But in its appeal Apple has scoffed at the notion that its watches are relying on Masimo’s patented technology, making a truce unlikely.
Having to pull its two top Apple Watches from the U.S. would put a small dent in the company’s annual sales of $383 billion. Although the company doesn’t disclose the volume of Apple Watch sales, analyst estimate the product accounts for about $18 billion in annual revenue.
The U.S. sales ban on the Series 9 and Ultra 2 won’t prevent Apple from continuing to sell its less-expensive model, called the SE, that isn’t equipped with a blood-oxygen sensor. But that technology, which Apple introduced into its watch lineup in 2020, has been a key part of the company’s effort to position the devices as life-saving tools to monitor users’ health.
In court filings urging the appeals court to continue blocking the sales ban, Apple argued that enforcing the ITC’s patent order would cause unnecessary harm to “a pioneering product made by a quintessentially American company that directly employs more than 90,000 employees” in the U.S.
Masimo argued that Apple won’t be significantly harmed by the U.S. sales ban of the Apple Watch models, given most of the company’s revenue comes from the iPhone. What’s more, Masimo sought to portray Apple as a corporate bully engaged in the brazen theft of intellectual property widely used in hospitals and other health professionals that treat about 200 million patients annually.
